| Names | |
|---|---|
| IUPAC name
3-[benzoyl(methyl)amino]-N-[2-bromo-4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-6-(trifluoromethyl)phenyl]-2-fluorobenzamide | |
| Identifiers | |
3D model (JSmol) |
|
| ChEBI | |
| ChemSpider | |
| ECHA InfoCard | 100.214.739 |
| EC Number |
|
| KEGG | |
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C25H14BrF11N2O2 | |
| Molar mass | 663.285 g·mol−1 |
| Hazards | |
| GHS labelling: | |
| Warning | |
| H410 | |
| P273, P391, P501 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Broflanilide is a complex, polycyclic, organohalogen insecticide which provides a novel mode of action (MoA).
Upon its discovery by Mitsui Chemicals, Insecticide Resistance Action Committee (IRAC) created the new MoA Group 30 for Broflanilide. Broflanilide is a meta-diamide GABA-gated Cl− channel allosteric modulator. This - along with isoxazolines providing the same MoA, so far only fluxametamide - constitute the new MoA Group 30 in the IRAC classification scheme.
The EPA has stated that Broflanilide is "Likely to be Carcinogenic to Humans".
Broflanilide meets the EPA Working Definition of PFAS. Note that "EPA considers any level of PFAS to be potentially toxicologically significant".
Products were registered in the United States in January, 2021, and in Canada. It is being sold under the brand names Cimegra (BASF) and Teraxxa (BASF, the seed treatment form).